(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazin-2-amine

ID: ALA4757177

PubChem CID: 11503332

Max Phase: Preclinical

Molecular Formula: C20H21Cl2FN6O

Molecular Weight: 451.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C[C@@H](Oc1nc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl

Standard InChI:  InChI=1S/C20H21Cl2FN6O/c1-11(17-14(21)2-3-15(23)18(17)22)30-20-19(24)26-9-16(28-20)12-8-27-29(10-12)13-4-6-25-7-5-13/h2-3,8-11,13,25H,4-7H2,1H3,(H2,24,26)/t11-/m1/s1

Standard InChI Key:  OUNTTYYPPFOKFB-LLVKDONJSA-N

Molfile:  

 
     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
   42.3687   -1.4527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.3676   -2.2723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0756   -2.6812    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   43.7853   -2.2718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7824   -1.4491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.0738   -1.0439    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   41.6599   -2.6776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.9137   -2.3447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.7744   -3.6596    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   41.5738   -3.4902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.4936   -2.6793    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   44.4949   -3.4965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.2033   -3.9040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.1999   -4.7185    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.9074   -5.1259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.6155   -4.7161    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.6116   -3.8947    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.9035   -3.4910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.7878   -3.9062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.8975   -2.6739    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   44.4916   -5.1261    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   47.3172   -3.4825    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   44.4886   -1.0379    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   40.3602   -2.9468    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   39.5435   -2.8582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.2153   -2.1088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.4067   -2.0188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9203   -2.6760    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   38.2485   -3.4254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.0631   -3.5177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  2  0
  8 24  1  0
  9 10  2  0
 10  7  1  0
  2  7  1  0
  4 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 12 19  1  1
 18 20  1  0
 14 21  1  0
 17 22  1  0
  5 23  1  0
  9 24  1  0
 25 26  1  0
 25 30  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 29 30  1  0
 24 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4757177

   3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyrazin-2-ylamine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 451.33

Molecular Weight (Monoisotopic): 450.1138

AlogP: 4.43

#Rotatable Bonds: 5

Polar Surface Area: 90.88

Molecular Species: BASE

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 10.12

CX LogP: 3.34

CX LogD: 0.73

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.56

Np Likeness Score: -1.10

References

1. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.,  28  (10): [PMID:29636220] [10.1016/j.bmcl.2018.03.032]

Source

Source(1):

• Scientific Literature